Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-620
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
DCTD
Cancer name
Triple-Negative Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Gemcitabine
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Up
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
36
Male patients
Not available
Female patients
Not available
Age range and number
11(<50)+25(>=50)
PMID
Description
Overexpression of miR-620 could contribute to the development of gemcitabine resistance in patients with TNBC via the direct downregulation of DCTD.
Tissue resource
triple-negative breast cancer samples
human triple-negative breast cancer cell lines MDA-MB-231
human triple-negative breast cancer cell lines BT549
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Liaocheng People's Hospital
American Type Culture Collection
Country
China
USA
Continent
Asia
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.